Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
N/A
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
3844-45-9
Name of the chemical
Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl-[(3-sulfophenyl)-methyl]-amino]-phenyl](2-sulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-3-sulfo, inner salts, disodium salt and its ammonium and aluminium salts (17); (CI 42090)
Concentration
N/A
EC/CAS
232-679-6
Name of the chemical
Starch
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
EC/CAS
223-339-8
Name of the chemical
Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl-[(3-sulfophenyl)-methyl]-amino]-phenyl](2-sulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-3-sulfo, inner salts, disodium salt and its ammonium and aluminium salts (17); (CI 42090)
Concentration
N/A
General Information
Revision date
2007-07-25
Product name
BREVINOR; SYNPHASE; NORIMIN
Emergency telephone
(24 hours) 1-800-424-9300
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
WARNING
Section 2
SECTION 2: Hazards identification
Appearance: White or Blue Tablet
Signal word
WARNING
Hazard statements
May cause cancer. May damage fertility or the unborn child.
Additional information
Short Term: Dust may be absorbed through the skin and cause systemic effects. May be harmful if swallowed. (based on components) . Accidental ingestion may cause effects similar to those seen in clinical use. Long Term: Occupational exposure to components of this mixture has resulted in menstrual irregularities in women and breast changes (enlargement, mammary secretions), loss of libido, and changes in sex hormone levels in men. Known Clinical Effects: The use of oral contraceptives is associated with increased risks of myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease. The most common adverse effects seen during clinical use of oral contraceptives are menstrual irregularities. EU Indication of danger: Carcinogenic: Category 1 Toxic to reproduction: Category 1 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child. R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. Australian Hazard Classification
Hazardous Ingredients
Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
